StreetInsider.com News Articles

Revolution (RVMD) PT Raised to $275 at Needham

Mon, 31 Aug 2026 07:20:17 -0400

(Updated - August 31, 2026 7:20 AM EDT)

Needham analyst Ami Fadia raised the price target on Revolution (NASDAQ: RVMD) to $275.00 (from $240.00) while maintaining a Buy rating.

The analyst commented: "We update our RVMD model for the approval and pricing of Rasonque which takes our PT up to $275. The WAC price which was announced at $39.8K for a 30-day supply with initial GtN expected to be in the range of 20-30% with higher rebates expected in indications with higher proportion of Medicare Part D population such as PDAC and CRC. The net price was higher than what we had

Revolution (RVMD) PT Raised to $275 at Needham

Mon, 31 Aug 2026 07:20:17 -0400

(Updated - August 31, 2026 7:20 AM EDT)

Needham analyst Ami Fadia raised the price target on Revolution (NASDAQ: RVMD) to $275.00 (from $240.00) while maintaining a Buy rating.

Revolution (RVMD) PT Raised to $275 at Guggenheim

Fri, 28 Aug 2026 08:12:51 -0400

(Updated - August 28, 2026 8:12 AM EDT)

Guggenheim analyst Michael Schmidt raised the price target on Revolution (NASDAQ: RVMD) to $275.00 (from $240.00) while maintaining a Buy rating.

The analyst commented: "Following yesterday's announcement of early FDA approval of daraxonrasib ("Rasonque") for patient with 2L mPDAC (see our earlier take here), RVMD held an investor call, and we subsequently connected with management to discuss further details on the approved label (here), pricing, reimbursement expectations, and launch-readiness in US and ROW. We highlight key takeaways below, and are updating our model to reflect the announced WAC price for Rasonque ($39,800/mo, vs. our

Revolution (RVMD) PT Raised to $275 at Guggenheim

Fri, 28 Aug 2026 08:12:51 -0400

(Updated - August 28, 2026 8:12 AM EDT)

Guggenheim analyst Michael Schmidt raised the price target on Revolution (NASDAQ: RVMD) to $275.00 (from $240.00) while maintaining a Buy rating.

Revolution (RVMD) PT Raised to $265 at UBS as Daraxonrasib Pricing Announced

Fri, 28 Aug 2026 07:16:46 -0400

UBS analyst Michael Yee raised the price target on Revolution (NASDAQ: RVMD) to $265.00 (from $220.00) while maintaining a Buy rating.

The analyst commented, "We are increasing our PT to $265 from $220 by adjusting to the announced price of daraxonrasib and increasing our 2026 and 2027 sales estimates for daraxonrasib. We have also increased the probability of success (PoS) to 100% following the drug's approval. Given these changes, we believe a higher multiple is warranted, as they increase our confidence in both the commercial outlook for the product and our overall investment thesis for the company. We now value RVMD

Revolution (RVMD) PT Raised to $265 at UBS as Daraxonrasib Pricing Announced

Fri, 28 Aug 2026 07:16:46 -0400

UBS analyst Michael Yee raised the price target on Revolution (NASDAQ: RVMD) to $265.00 (from $220.00) while maintaining a Buy rating.

Revolution (RVMD) PT Raised to $246 at JPMorgan

Thu, 27 Aug 2026 08:30:51 -0400

JPMorgan analyst Brian Cheng raised the price target on Revolution (NASDAQ: RVMD) to $246.00 (from $227.00) while maintaining a Overweight rating.

Revolution (RVMD) PT Raised to $251 at RBC Capital

Thu, 27 Aug 2026 07:55:24 -0400

RBC Capital analyst Leonid Timashev raised the price target on Revolution (NASDAQ: RVMD) to $251.00 (from $203.00) while maintaining a Outperform rating.

Revolution (RVMD) PT Raised to $280 at H.C. Wainwright

Thu, 27 Aug 2026 07:00:33 -0400

(Updated - August 27, 2026 7:00 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Revolution (NASDAQ: RVMD) to $280.00 (from $195.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Revolution Medicines announced that the FDA approved RASONQUE (daraxonrasib), an oral RAS(ON) multi-selective inhibitor, for the treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least 1 prior systemic therapy and are not candidates for multiagent systemic therapy. The application was reviewed under the FDA Commissioner’s National Priority Voucher pilot program, which the agency accepted for review on July 22, 2026, with an anticipated

Revolution (RVMD) PT Raised to $280 at H.C. Wainwright

Thu, 27 Aug 2026 07:00:33 -0400

(Updated - August 27, 2026 7:00 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Revolution (NASDAQ: RVMD) to $280.00 (from $195.00) while maintaining a Buy rating.

Revolution (RVMD) PT Raised to $239 at Truist Securities

Thu, 27 Aug 2026 06:59:19 -0400

Truist Securities analyst Gregory Renza raised the price target on Revolution (NASDAQ: RVMD) to $239.00 (from $231.00) while maintaining a Buy rating.

Revolution (RVMD) PT Raised to $260 at Oppenheimer

Wed, 26 Aug 2026 17:01:32 -0400

(Updated - August 26, 2026 5:01 PM EDT)

Oppenheimer analyst Jay Olson raised the price target on Revolution (NASDAQ: RVMD) to $260.00 (from $230.00) while maintaining a Outperform rating.

The analyst commented: "We view today's FDA approval of RASONQUE (daraxonrasib) as a transformative event for RVMD and a landmark moment for metastatic pancreatic ductal adenocarcinoma (PDAC) based on the approved label, which exceeded investor expectations by including not only previously treated metastatic PDAC patients but also patients who are not candidates for multiagent systemic therapy, thus creating a meaningful opportunity for first-line utilization at physician discretion. The approval is supported by unprecedented

Revolution (RVMD) PT Raised to $260 at Oppenheimer

Wed, 26 Aug 2026 17:01:32 -0400

(Updated - August 26, 2026 5:01 PM EDT)

Oppenheimer analyst Jay Olson raised the price target on Revolution (NASDAQ: RVMD) to $260.00 (from $230.00) while maintaining a Outperform rating.

Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution